Prognostic significance of ERCC1 expression in resected non small cell lung carcinoma

Annals of Thoracic and Cardiovascular Surgery

Volumn 17, Issue 2, 2011, Pages 110-117

  Seyhan, Ekrem Cengiz ^a   Altin, Sedat ^a   Çetinkaya, Erdogan ^a   Sökücü, Sinem ^a   Abali, Hülya ^a   Buyukpinarbasili, Nur ^a   Fener, Neslihan ^a  

^a Yedikule Teaching Hospital   (Turkey)

Author keywords

Excision repair cross complementation 1; Immunochemistry; Non small cell lung carcinoma

Indexed keywords

EID: 79955615272     PISSN: 13411098     EISSN: None     Source Type: Journal    
DOI: 10.5761/atcs.oa.09.01526     Document Type: Article

References (21)

1. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-7.
2. Pairolero PC, Williams DE, Bergstralh EJ, Piehler JM, Bernatz PE, et al. Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg 1984; 38: 331-8.
3. Le Chevalier T, Arriagada R, Pignon JP, Scagliotti GV. Should adjuvant chemotherapy become standard treatment in all patients with resected nonsmall-cell lung cancer? Lancet Oncol 2005; 6: 182-84.
4. Strauss GM, Kwiatkowski DJ, Harpole DH, Lynch TJ, Skarin AT, et al. Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung. J Clin Oncol 1995; 13: 1265-79.
5. Rosell R, Skrzypski M, Jassem E, Taron M, Bartolucci R, et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One 2007; 2: 1129.
6. Lee KH, Min HS, Han SW, Oh DY, Lee SH, et al. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer 2008; 60: 401-7.
7. Zheng Z, Li X, Schell MJ, Chen T, Boulware D, et al. Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer 2008; 112: 2765-73.
8. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005; 127: 978-83.
9. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-1.
10. Okuda K, Sasaki H, Dumontet C, Kawano O, Yukiue H, et al. Expression of excision repair cross-complementation group 1 and class III beta tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer 2008; 62: 105-12.
11. Zheng Z, Chen T, Li X, Haura E, Sharma A, et al. The DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007; 356: 800-8.
12. Li Q, Yu JJ, Mu C, Yunmbam MK, Slavsky D, et al. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 2000; 20: 645-52.
13. Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16: 309-16.
14. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001; 19: 4298-30.
15. Azuma K, Komohara Y, Sasada T, Terazaki Y, Ikeda J, et al. Excision repair cross-complementation group 1 predicts progression-free and overall survival in nonsmall cell lung cancer patients treated with platinumbased chemotherapy. Cancer Sci 2007; 98: 1336-43.
16. Rosell R, Felip E, Taron M, Majo J, Mendez P, et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 2004; 10: 4215-19.
17. Wei Q, Frazier ML, Levin B. DNA repair: a doubleedged sword. J Natl Cancer Inst 2000; 92: 440-1.
18. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8: 2286-91.
19. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histological typing of tumours of lung and pleura. In: Sobin LH, ed. World Health Organization International Classification of Tumours, 3rd ed. Berlin, Germany: Springer-Verlag, 1999.
20. Al Haddad S, Zhang Z, Leygue E, Snell L, Huang A, et al. Psoriasin (S100A7) expression and invasive breast cancer. Am J Pathol 1999; 155: 2057-66.
21. Volm M, Hahn EW, Mattern J, Müller T, Vogt-Moykopf I, et al. Five-year follow-up study of independent clinical and flow cytometric prognostic factors for the survival of patients with non-small cell lung carcinoma. Cancer Res 1988; 48: 2923-28.